Journal of Neuro-Oncology ( IF 3.2 ) Pub Date : 2022-11-15 , DOI: 10.1007/s11060-022-04184-4
Abdurrahman I Islim 1, 2 , Jing X Lee 3 , Mohammad A Mustafa 1, 2 , Christopher P Millward 1, 2 , Conor S Gillespie 1, 2 , George E Richardson 1, 2 , Basel A Taweel 1, 2 , Emmanuel Chavredakis 1, 2 , Samantha J Mills 4 , Andrew R Brodbelt 1, 2 , Michael D Jenkinson 1, 2
|
Background
Sporadic multiple meningioma are uncommon. Population-based data suggests that these patients have a reduced overall survival when compared to patients with solitary meningioma. The aim of this study was to investigate the clinical outcomes in multiple and solitary meningioma.
Methods
A single-center matched cohort study (2008–2018) was performed. Patients with synchronous multiple meningioma at presentation, with no history of prior intracranial radiation, concurrent hormone replacement therapy or features of NF2-schwannomatosis were included. Eligible patients were matched 1:1 to patients with solitary meningioma. Outcomes of interest were occurrence of an intervention, recurrence, new meningioma development and mortality.
Results
Thirty-four patients harboring 76 meningioma at presentation were included. Mean age was 59.3 years (SD = 13.5). Thirty-one (91.2%) were female. The median number of meningioma per patient was 2 (range 2–6). Eighteen patients (52.9%) were symptomatic at presentation. Median overall follow-up was 80.6 months (IQR 44.1–99.6). Compared to patients with a sporadic meningioma, there was no difference in intervention rates (67.6% vs 70.6%, P = 0.792). Eight patients (34.8%) with a multiple meningioma had a WHO grade 2 meningioma compared to 7 (29.2%) with a solitary meningioma (P = 0.679). Median recurrence-free survival was 89 months (95% CI 76–104) with no difference between the two groups (P = 0.209). Mean overall survival was 132 months (95% CI 127–138) with no difference between the two groups (P = 0.860). One patient with multiple meningioma developed two further new meningioma 36 months following diagnosis.
Conclusion
Sporadic multiple meningioma may not have worse clinical outcomes. Management of patients with sporadic multiple meningioma should be tailored towards the symptomatic meningioma or high-risk asymptomatic meningioma.
中文翻译:
![](https://scdn.x-mol.com/jcss/images/paperTranslation.png)
散发性多发性颅内脑膜瘤并不意味着患者预后较差:病例对照研究的结果
背景
散发性多发性脑膜瘤并不常见。基于人群的数据表明,与孤立性脑膜瘤患者相比,这些患者的总体生存率较低。本研究的目的是调查多发性和孤立性脑膜瘤的临床结果。
方法
进行了一项单中心匹配队列研究(2008-2018 年)。包括就诊时患有同时性多发性脑膜瘤、既往无颅内放射史、并发激素替代治疗或 NF2-神经鞘瘤病特征的患者。符合条件的患者与孤立性脑膜瘤患者 1:1 匹配。感兴趣的结果是干预的发生、复发、新脑膜瘤的发展和死亡率。
结果
包括 34 名在就诊时携带 76 个脑膜瘤的患者。平均年龄为 59.3 岁 (SD = 13.5)。三十一名 (91.2%) 为女性。每个患者脑膜瘤的中位数为 2(范围 2-6)。18 名患者 (52.9%) 在就诊时出现症状。中位总体随访时间为 80.6 个月 (IQR 44.1–99.6)。与散发性脑膜瘤患者相比,干预率无差异(67.6% 对 70.6%,P = 0.792)。8 名患有多发性脑膜瘤的患者 (34.8%) 患有 WHO 2 级脑膜瘤,而 7 名 (29.2%) 患有孤立性脑膜瘤 (P = 0.679)。中位无复发生存期为 89 个月 (95% CI 76–104),两组间无差异 (P = 0.209)。平均总生存期为 132 个月 (95% CI 127–138),两组间无差异 (P = 0.860)。
结论
散发性多发性脑膜瘤可能不会有更差的临床结果。散发性多发性脑膜瘤患者的管理应针对有症状的脑膜瘤或高危无症状脑膜瘤。